Compare PIII & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | CVM |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 30.1M |
| IPO Year | 2021 | 1996 |
| Metric | PIII | CVM |
|---|---|---|
| Price | $5.50 | $1.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.00 | $12.50 |
| AVG Volume (30 Days) | 11.0K | ★ 232.1K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,459,080,000.00 | $264,033.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $9.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.52 | $0.89 |
| 52 Week High | $16.89 | $10.24 |
| Indicator | PIII | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 18.00 | 51.74 |
| Support Level | $2.39 | $1.01 |
| Resistance Level | $11.55 | $4.84 |
| Average True Range (ATR) | 0.35 | 0.25 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 0.00 | 22.55 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.